Level-1 Data From the REDUCE Study and the PCPT Data

The document discussed two major studies evaluating the impact of 5-alpha-reductase inhibitors on prostate cancer risk. The Prostate Cancer Prevention Trial focused on men with low baseline PSA levels and found that finasteride significantly reduced the risk of prostate cancer detection, although it was associated with an increased diagnosis of higher-grade disease. The REDUCE trial examined the effects of dutasteride in men with elevated PSA levels, showing a significant reduction in prostate cancer risk without a statistical increase in higher-risk disease compared to placebo.